NEUROCRINE BIOSCIENCES INC Earnings Per Share Disclosure
Year Ended December 31, | |||||||||||||||||
| (in millions, except per share data) | 2025 | 2024 | 2023 | ||||||||||||||
| Net income - basic and diluted | $ | 478.6 | $ | 341.3 | $ | 249.7 | |||||||||||
| Weighted-average common shares outstanding: | |||||||||||||||||
| Basic | 99.5 | 100.4 | 97.7 | ||||||||||||||
| Effect of dilutive securities | 3.0 | 3.3 | 3.3 | ||||||||||||||
| Diluted | 102.5 | 103.7 | 101.0 | ||||||||||||||
| Earnings per share: | |||||||||||||||||
| Basic | $ | 4.81 | $ | 3.40 | $ | 2.56 | |||||||||||
| Diluted | $ | 4.67 | $ | 3.29 | $ | 2.47 | |||||||||||
Shares excluded from diluted per share amounts because their effect would have been anti-dilutive | 4.0 | 2.4 | 4.7 | ||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 11, 2026 | Showing above |
| 2024 | Feb 10, 2025 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.